前收市價 | 29.22 |
開市 | 28.99 |
買盤 | 28.87 x 100 |
賣出價 | 28.96 x 100 |
今日波幅 | 28.82 - 29.20 |
52 週波幅 | 28.82 - 45.21 |
成交量 | |
平均成交量 | 125,535 |
市值 | 1.918B |
Beta 值 (5 年,每月) | 0.02 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.06 |
業績公佈日 | 無 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 41.43 |
The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]